At baseline, ctDNA positivity predicted worse two-year EFS in both arms, yet EV+Pembro still outperformed chemotherapy in positive and negative patients. The hosts found no predictive signal, and ctDNA-negative patients on chemotherapy still faced roughly 15–20% relapse risk, so baseline results should not guide de-escalation.
Tom noted post-surgery ctDNA positivity fell to 5% on EV+Pembro versus 15% on chemotherapy, and the chemo arm also declined. He suspects surgery accounts for only part of the drop, with delayed immune clearance from EV+Pembro contributing; the durability of response evolves over months. So the surgical effect is not the whole story.
Tom noted 24-month EFS was 94% in EV+Pembro patients who were ctDNA-negative at baseline and stayed negative, but John Chatzko cautioned that about a quarter of pre-surgery ctDNA-negative EV+Pembro patients still lacked pCR. They favored randomized de-escalation trials over routine treatment reduction; the high survival is real, but causal attribution is not.
Tom said patients who remain ctDNA-positive after surgery, roughly 18 weeks out, have a median PFS of only about four months and do very poorly regardless of prior therapy. John Chatzko called this an unmet need and pointed to an upcoming adjuvant DATO-DXD trial as a possible option.
John Chatzko said the fourth adjuvant sample was not readily interpretable because of patient attrition, possible test failures, and schedule differences: EV+Pembro was drawn at adjuvant cycle eight day one, gem/cis at surveillance. Tom warned that aspirational serial-testing designs will lose patients, as even INVIGOR-11 struggled to retain them.
John Chatzko reported that 82% of baseline ctDNA-positive patients cleared ctDNA before surgery on EV+Pembro versus 67% on gem/cis. Among those clearers, two-year EFS was 81% versus 63%, suggesting EV+Pembro drives a deeper biologic response. That gap implies the quality, not just frequency, of clearance differs by regimen.
Tom argued pCR reflects local drug activity in the bladder and matters less when everyone undergoes cystectomy, while ctDNA reflects clearance of micrometastases. Their imperfect alignment is expected because the tests measure different processes and have different sensitivity and specificity. Neither is a complete proxy for the other.
Tom said no pre-surgery ctDNA-positive patient achieved pCR in EV304 or Niagara. Among ctDNA-negative patients, pCR was 75% with EV+Pembro but roughly 50-50 with chemotherapy. That makes bladder-sparing risky while ctDNA remains positive; the test is not a green light for less local therapy.
